• Agreement paves way for joint Peptide Discovery and Optimisation Partnership
    Orbit Discovery is based in the Oxford Science Park's Schrodinger Building
  • Credit Orbit Discovery

News & Views

Agreement paves way for joint Peptide Discovery and Optimisation Partnership

Mar 18 2022

Peptide technology company Orbit Discovery has announced a partnership with WuXi AppTec that will see the combination of its peptide discovery platform and experience with the Chinese organisation’s downstream capabilities as a leading global provider of R&D and manufacturing services provision for the pharmaceutical and healthcare industry.

Specifically, Orbit gains access to WuXi AppTec’s expertise in peptide optimisation, peptide production and manufacturing to help its partners obtain clinically relevant data packs and materials in a rapid timeframe. Incorporating these capabilities into the Orbit platform will enable functional assays to be developed against a wider range of targets, facilitating direct functional screens using novel bead-based technologies and microfluidics.

This is the first strategic technology link Orbit has penned since its formation in 2016. The partnership underlines the commitment of the new management team to deliver ground-breaking technology and broader capabilities to the Partners engaged in applying the Company’s technology for the discovery of peptide therapeutic leads.

Dr Neil Butt, Chief Executive Officer of Orbit Discovery, commented: “We aim to move Orbit to the forefront of peptide discovery, and relationships such as this help us leverage expertise that would take far longer to grow organically. We see the partnership with WuXi AppTec as being a key relationship and a great asset to our current Partners, and Partners of the future.” He added: “We see particular value in the development and manufacturing platform of WuXi AppTec, that will enable us to generate peptides at small or large scale that incorporate chemical modifications to facilitate peptide optimisations and the journey towards a therapeutic candidate.”

“We are very pleased to have the opportunity to support Orbit Discovery and its research partners” commented Dr Dave Madge, VP Discovery Services at WuXi AppTec. “We see substantial synergies between the Orbit technology for peptide discovery and our platform for optimisation, characterisation and manufacture of novel peptide therapeutics.”

More information online


Digital Edition

Lab Asia 29.6 Dec

December 2022

In This Edition Chromatography - Optimising Viral Vector Purification Strategies with Multimodal Chromatography - Key UHPLC Characteristics Required for High throughput LC-MS - New Low Volu...

View all digital editions

Events

Medlab Middle East

Feb 06 2023 Dubai, UAE

FILTECH

Feb 14 2023 Cologne, Germany

SmartLab Exchange

Feb 22 2023 Amsterdam, Netherlands

SLAS 2023

Feb 25 2023 San Diego, CA, USA

View all events